Halstead Michael
Known title: Chief Executive OfficerCIK: 0001521548
Halstead Michael's purchase track record
Halstead Michael has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/21/2026 | HELP | $1.35M | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| HELP | ▲ Buy | Open Market | 100,000 | $1.3M | 9/21/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Cybin shareholders approve rebrand to Helus Pharma
Cybin shareholders recently approved a plan to change the company's name to Helus Pharma, effective October 1, 2026. This rebrand coincides with the company's focus on its HLP-003 drug for major depression, which is awaiting Phase III data. While the stock has seen fresh attention, analysts note it may be trading at a premium relative to its current valuation metrics.
Cybin shareholders approve rebrand to Helus Pharma. Cybin shareholders recently approved a plan to change the company's name to Helus Pharma, effective October 1, 2026. This rebrand coincides with the company's focus on its HLP-003 drug for major depression, which is awaiting Phase III data. While the stock has seen fresh attention, analysts note it may be trading at a premium relative to its current valuation metrics.